Fidelity Growth Partners Asia and Fidelity Biosciences have committed 62.5 million yuan ($10 million) to Eyebright Medical Technology, a Beijing-based ophthalmic medical devices manufacturer.
Xie Jiangbing, chairman of Eyebright said that the company's goal is to become the largest manufacturer of artificial crystal in China and to allow Chinese cataract patients to enjoy a low price but high quality products.
"We will develop other ophthalmology medical products and expand the international market according to our long-term plans. With Fidelity's investment, we will introduce foreign advanced medical technology and expand our product line to meet the growing demand for medical products among Chinese people," Xie added.
Dr Fang Yu, partner of Fidelity Growth Partners Asia, said that Fidelity is very optimistic about the development of China's medical industry in the next 10 to 20 years and has been committed to investing in domestic outstanding enterprises.
Fidelity has rich resources in domestic and foreign ophthalmology services and has also been concerned about related enterprises. Eyebright has a strong R&D and production capacity in artificial crystal and other ophthalmology products. He hopes that Eyebright could become a leading company in producing ophthalmology products through cooperation with Fidelity.